132 related articles for article (PubMed ID: 7705706)
1. Interleukin-12-mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system.
DeCesare SL; Michelini-Norris B; Blanchard DK; Barton DP; Cavanagh D; Roberts WS; Fiorica JV; Hoffman MS; Djeu JY
Gynecol Oncol; 1995 Apr; 57(1):86-95. PubMed ID: 7705706
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-12 synergizes with interleukin-2 to generate lymphokine-activated killer activity in peripheral blood mononuclear cells cultured in ovarian cancer ascitic fluid.
Barton DP; Blanchard DK; Duan C; Roberts WS; Cavanagh D; DeCesare S; Djeu JY
J Soc Gynecol Investig; 1995; 2(6):762-71. PubMed ID: 9420887
[TBL] [Abstract][Full Text] [Related]
3. Infiltration of interleukin-2-inducible killer cells in ascitic fluid and pleural effusions of advanced cancer patients.
Blanchard DK; Kavanagh JJ; Sinkovics JG; Cavanagh D; Hewitt SM; Djeu JY
Cancer Res; 1988 Nov; 48(22):6321-7. PubMed ID: 2972357
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer activity of tumor-associated and peripheral blood lymphocytes isolated from patients with ascites ovarian tumors.
Allavena P; Zanaboni F; Rossini S; Merendino A; Bonazzi C; Vassena L; Mangioni C; Mantovani A
J Natl Cancer Inst; 1986 Oct; 77(4):863-8. PubMed ID: 3489856
[TBL] [Abstract][Full Text] [Related]
5. Cross regulation by IL-10 and IL-2/IL-12 of the helper T cells and the cytolytic activity of lymphocytes from malignant effusions of lung cancer patients.
Chen YM; Yang WK; Ting CC; Tsai WY; Yang DM; Whang-Peng J; Perng RP
Chest; 1997 Oct; 112(4):960-6. PubMed ID: 9377959
[TBL] [Abstract][Full Text] [Related]
6. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor.
Hirte H; Clark DA
Cancer Immunol Immunother; 1991; 32(5):296-302. PubMed ID: 1998971
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-12 augments cytolytic activity of peripheral blood mononuclear cells against autologous lung cancer cells in combination with IL-2.
Hiraki A; Kiura K; Yamane H; Nogami N; Tabata M; Takigawa N; Ueoka H; Tanimoto M; Harada M
Lung Cancer; 2002 Mar; 35(3):329-33. PubMed ID: 11844609
[TBL] [Abstract][Full Text] [Related]
8. Stimulation of natural killer activity in peripheral blood lymphocytes of healthy donors and melanoma patients in vitro: synergism between interleukin (IL)-12 and IL-15 or IL-12 and IL-2.
Seidel MG; Freissmuth M; Pehamberger H; Micksche M
Naunyn Schmiedebergs Arch Pharmacol; 1998 Sep; 358(3):382-9. PubMed ID: 9774227
[TBL] [Abstract][Full Text] [Related]
9. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
Wang YL; Si LS; Kanbour A; Herberman RB; Whiteside TL
Cancer Res; 1989 Nov; 49(21):5979-85. PubMed ID: 2507139
[TBL] [Abstract][Full Text] [Related]
10. Comparison of natural killer activity of human bone marrow and blood cells in cultures containing IL-2, IL-7 and IL-12.
Wong EK; Eaves C; Klingemann HG
Bone Marrow Transplant; 1996 Jul; 18(1):63-71. PubMed ID: 8831997
[TBL] [Abstract][Full Text] [Related]
11. In vitro induction of tumor-specific human lymphocyte antigen class I-restricted CD8 cytotoxic T lymphocytes by ovarian tumor antigen-pulsed autologous dendritic cells from patients with advanced ovarian cancer.
Santin AD; Hermonat PL; Ravaggi A; Bellone S; Pecorelli S; Cannon MJ; Parham GP
Am J Obstet Gynecol; 2000 Sep; 183(3):601-9. PubMed ID: 10992180
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo cytokine activation of peripheral blood stem cells: a potential role for adoptive cellular immunotherapy.
Meehan KR; Wu A; Hassan R; Miao Y; Chawla J; Slack R; Gehan E; Herscowitz HB
J Hematother Stem Cell Res; 2001 Apr; 10(2):283-90. PubMed ID: 11359675
[TBL] [Abstract][Full Text] [Related]
13. Effector function of lymphokine-activated killer cells and cytotoxic T lymphocytes in ovarian epithelial carcinoma.
Lentz SS; Kovach JS; McKean DJ; Wieand HS; Podratz KC
Gynecol Oncol; 1990 Aug; 38(2):191-6. PubMed ID: 2387535
[TBL] [Abstract][Full Text] [Related]
14. Human recombinant IL-4 decreases the emergence of non-specific cytolytic cells and favours the appearance of memory cells (CD4+CD45RO+) in the IL-2-driven development of cytotoxic T lymphocytes against autologous ovarian tumour cells.
Roth AD; Dupuis S; Alberto P
Clin Exp Immunol; 1995 Aug; 101(2):362-8. PubMed ID: 7648722
[TBL] [Abstract][Full Text] [Related]
15. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Owen-Schaub LB; Gutterman JU; Grimm EA
Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte colony-stimulating factor suppresses autologous tumor killing activity of the peripheral blood lymphocytes in the patients with ovarian carcinoma.
Ohta Y; Hayakawa S; Karasaki-Suzuki M; Sugita K; Komine S; Chishima F; Hatta Y; Horie T; Seo N; Sheikh A; Nemoto N; Yamamoto T
Am J Reprod Immunol; 2004 Jul; 52(1):81-7. PubMed ID: 15214947
[TBL] [Abstract][Full Text] [Related]
17. Interferon effect on cytotoxicity of peripheral blood and tumor-associated lymphocytes against human ovarian carcinoma cells.
Allavena P; Introna M; Sessa C; Mangioni C; Mantovani A
J Natl Cancer Inst; 1982 Apr; 68(4):555-62. PubMed ID: 6175786
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 1 beta synergises with interleukin 2 in the outgrowth of autologous tumour-reactive CD8+ effectors.
Baxevanis CN; Dedoussis GV; Gritzapis AD; Stathopoulos GP; Papamichail M
Br J Cancer; 1994 Oct; 70(4):625-30. PubMed ID: 7917907
[TBL] [Abstract][Full Text] [Related]
19. Lymphocyte activation by recombinant interleukin-2 in ovarian cancer patients.
Boyer PJ; Berek JS; Zighelboim J
Obstet Gynecol; 1989 May; 73(5 Pt 1):793-7. PubMed ID: 2784847
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
